Last reviewed · How we verify
EQW plus DAPA
EQW (semaglutide) is a GLP-1 receptor agonist combined with DAPA (dapagliflozin), an SGLT2 inhibitor, to provide dual glucose-lowering effects through incretin mimicry and urinary glucose excretion.
EQW (semaglutide) is a GLP-1 receptor agonist combined with DAPA (dapagliflozin), an SGLT2 inhibitor, to provide dual glucose-lowering effects through incretin mimicry and urinary glucose excretion. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | EQW plus DAPA |
|---|---|
| Also known as | Bydureon plus Farxiga, Long acting GLP1 agonist plus SGLT2 inhibitor |
| Sponsor | Woman's |
| Drug class | GLP-1 receptor agonist + SGLT2 inhibitor combination |
| Target | GLP-1 receptor; SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Semaglutide activates GLP-1 receptors to enhance insulin secretion, suppress glucagon, and slow gastric emptying. Dapagliflozin inhibits sodium-glucose cotransporter 2 in the kidney to increase urinary glucose excretion. Together, they provide complementary mechanisms for glycemic control and cardiovascular/renal benefits in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Genital mycotic infections
- Urinary tract infections
- Hypoglycemia
Key clinical trials
- EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EQW plus DAPA CI brief — competitive landscape report
- EQW plus DAPA updates RSS · CI watch RSS
- Woman's portfolio CI